Chambers Rebecca

CFO Chambers sells 18,341 shares at $35.55–$36.33; stock down 24.1% in 90 days, now trading 31.4% below 52-week high.

Rebecca Chambers, CFO of Veracyte, executed 2 separate sales totaling 18,341 shares for $662,869.24 at an average price of $36.14 on 2026-03-04, reducing her holdings by 12.3% to 131,196 shares. The timing coincides with significant downward price momentum: the stock has declined 24.1% over the prior 90 days and trades 31.4% below its 52-week high of $49.38. Her prior trades at VCYT show a pattern of 2 of 3 well-timed sells at the 90-day mark, most recently in December with 90-day declines of -22.2% and -23.2%. The current sales occur at a price point ($36.14) notably above the current market price of $33.85, suggesting execution during relative strength within a broader downtrend. Given the company's solid fundamentals—revenue of $131,872,000.00 with 16.0% annual growth and net income of $19,137,000.00—the sales do not accompany deteriorating business metrics, though the valuation at P/E 37.20 remains elevated relative to recent price action.

CFO Rebecca Chambers sold 13,278 VCYT shares for $621,955.21 across 2 transactions on 2025-12-04.

Rebecca Chambers, CFO of Veracyte Inc., executed 2 separate sales totaling 13,278 shares for $621,955.21 on 2025-12-04, reducing her holdings by 10.8% from 122.8K to 109.5K shares. The sales occurred at prices of $46.61 and $47.25 respectively, with a blended average of $46.84, near the current price of $47.41. Her cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 0.00%, and at VCYT specifically, her lone prior sale on 2024-11-12 generated +9.4% returns over 90 days (poorly timed, as the stock subsequently rose). The company trades at a P/E of 124.76 with annual revenue growth of +23.5%, and the stock is currently +31.3% over 30 days and +46.2% over 90 days, placing it 4.0% below its 52-week high. The timing and magnitude of this sale merit observation given the elevated valuation and recent sharp appreciation, though the absence of a pattern of well-timed sales at this ticker limits inference about forward-looking conviction.

CFO Rebecca Chambers sold 15,275 shares of VCYT at $38.34; holds 124,501 shares post-sale

Rebecca Chambers, Chief Financial Officer of Veracyte Inc., sold 15,275 shares at $38.34 on 2024-11-12, reducing her holdings by 10.9% to 124,501 shares. The sale occurred near the company's 52-week high of $39.53, with the stock currently trading at $37.04. While the company showed strong recent performance (revenue of $115,860,000 in the latest quarter, annual revenue growth of 21.8%, and positive net income of $15,155,000 in that period), Veracyte reported negative full-year net income over its most recent complete fiscal year, indicating ongoing profitability challenges despite quarterly improvements. This represents a material open-market sale by a senior executive at a significant price level, warranting monitoring of company performance trends and any subsequent insider activity patterns.